Trial · NCT07906795
FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma
NCT07906795, Completed, Amina Fouad Farag
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma. Trials, record NCT07906795. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906795
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma
- NCT number
- NCT07906795
- Status
- Completed
- Enrollment
- 62 participants, actual
- Lead sponsor
- Amina Fouad Farag
- Conditions
- Oral Leukoplakia (OL), Oral Squamous Cell Carcinoma (OSCC)
- First posted
- 2026-10-30
- Last updated
- 2026-11-04
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Diagnostic potential of FENDRR, CRNDE, DUSP1 and DMBT1 | From enrollment to August 29, 2023 | Expression of lncRNA-FENDRR and lncRNA-CRNDE (relative expression, 2\^-ΔΔCt, by real-time RT-PCR) and tissue levels of DUSP1 (pg/mg protein) and DMBT1 (ng/mg protein, by ELISA) are measured in each tissue specimen. Diagnostic accuracy is assessed with receiver operating characteristic (ROC) curve analysis: area under the curve (AUC) with 95% confidence interval, and sensitivity and specificity, for oral leukoplakia versus controls, oral squamous cell carcinoma versus controls, and oral squamous cell carcinoma versus oral leukoplakia. Accuracy is compared with PI3K, AKT, mTOR, ERK2 and MMP9 measured in the same specimens. |
| Secondary | Association of biomarker expression with clinicopathological characteristics | From enrollment to August 29, 2023 | Within the oral leukoplakia and oral squamous cell carcinoma groups, patients are classified as having favourable or unfavourable expression of each biomarker at the group median (unfavourable: low FENDRR, high CRNDE, low DUSP1, low DMBT1). Each category is compared with age, sex, lesion site and size, clinical presentation (oral leukoplakia), histopathological grade, clinical stage, degree of invasion, invasive front, lymph node metastasis and distant metastasis (oral squamous cell carcinoma). Results are reported as the number (%) of patients with unfavourable expression in each category, compared with the Fisher exact test. |
| Secondary | Prognostic significance of biomarker expression for disease-free and overall survival | August 29, 2025 (24 months follow-up after surgery) | Patients with oral leukoplakia and oral squamous cell carcinoma are followed after surgery. Disease-free survival is the time from surgery to recurrence, or, for oral leukoplakia, recurrence or malignant transformation. Overall survival is the time from surgery to death from the disease. Survival is compared between favourable and unfavourable expression of each biomarker, and of combined FENDRR/CRNDE and DUSP1/DMBT1 profiles, using Kaplan-Meier curves with the log-rank test. Univariate Cox proportional hazards regression gives hazard ratios with 95% confidence intervals. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906795
GET https://conductscience.org/api/trials/v1/NCT07906795/registered